georgeclerk B Riley has initiated Centessa Pharmaceuticals ( NASDAQ: CNTA ) with a buy rating citing the potential of the company's orexin 2 receptor agonists for sleep disorders. The firm has a $33 price target (~110% upside based on Sept. 18 close).
Centessa has.
